APMD NASDAQ
Apnimed, Inc.
1W: -5.7%
1M: -1.6%
YTD: +63.9%
$26.23
-0.57 (-2.13%)
Weekly Expected Move ±13.1%
$19
$23
$26
$30
$33
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.0B
52W Range16.12-35.29
Volume207,749
Avg Volume450,555
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOKevin R. Lind
Employees65
SectorHealthcare
IndustryBiotechnology
IPO Date2026-07-29
Websiteapnimed.com
39 John F. Kennedy Street
Cambridge, MA 02138
US
Cambridge, MA 02138
US
About Apnimed, Inc.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Latest News
Apnimed, Inc. reports Q2 results
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Apnimed, Inc.’s Quiet Period Will End on September 9th (NASDAQ:APMD)
APMD | Apnimed, Inc. Common Stock Stock Data, Price & News - Quiver Quantitative
BofA makes bullish call on newly public biotech stock
Recent Insider Trades
No insider trades found